ImageneBio (NASDAQ:IMA) Releases Earnings Results

ImageneBio (NASDAQ:IMA) posted its quarterly earnings results on Tuesday. The company reported $0.34 EPS for the quarter, FiscalAI reports.

ImageneBio Price Performance

Shares of IMA opened at $6.07 on Wednesday. The company has a market capitalization of $67.86 million, a price-to-earnings ratio of -0.75 and a beta of 0.44. The business’s 50-day moving average is $6.78 and its 200-day moving average is $7.66. ImageneBio has a fifty-two week low of $5.70 and a fifty-two week high of $18.00.

Insider Activity

In related news, Director Joseph P. Slattery bought 16,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 24th. The shares were acquired at an average price of $5.99 per share, with a total value of $95,840.00. Following the completion of the transaction, the director owned 16,000 shares of the company’s stock, valued at $95,840. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.94% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ImageneBio

Hedge funds have recently modified their holdings of the business. Millennium Management LLC bought a new stake in shares of ImageneBio in the 4th quarter valued at about $79,000. Squarepoint Ops LLC increased its stake in shares of ImageneBio by 99.6% during the fourth quarter. Squarepoint Ops LLC now owns 48,237 shares of the company’s stock worth $333,000 after purchasing an additional 24,067 shares during the period. Barclays PLC boosted its position in shares of ImageneBio by 170.8% in the fourth quarter. Barclays PLC now owns 10,797 shares of the company’s stock valued at $74,000 after acquiring an additional 6,810 shares during the period. Jane Street Group LLC acquired a new stake in ImageneBio in the 4th quarter worth about $103,000. Finally, DRW Securities LLC acquired a new stake in shares of ImageneBio in the fourth quarter valued at approximately $302,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on IMA shares. Wall Street Zen downgraded ImageneBio from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Wedbush downgraded shares of ImageneBio from a “neutral” rating to an “underperform” rating in a research report on Tuesday, November 25th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, ImageneBio has a consensus rating of “Hold” and a consensus price target of $26.50.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.